started · updated
Diabetes prevalence and treatment costs rise in Czechia
Diabetes prevalence in Czechia is increasing, with approximately 1.2 million people currently living with the condition. Projections suggest this number will reach 1.3 million by 2030. To combat this trend, medical professionals are shifting their focus toward prediabetes to prevent the full development of type 2 diabetes.
Medical experts, including Professor Martin Prázný of the Czech Diabetes Society, have warned that failing to intervene in high-risk patients could cost the country approximately 18 billion CZK annually. Current care for diabetics in Czechia exceeds 120 billion CZK per year. To mitigate long-term costs and complications, doctors are implementing regular blood glucose testing during biennial check-ups without age restrictions.
Data from the Health Insurance Fund of the Ministry of the Interior (ZP MV ČR) shows that costs for treating type 2 diabetes rose by over 600 million CZK between 2021 and 2025, a 45 percent increase. During this period, the number of insured clients receiving such care grew by 14 percent to nearly 114,000. The average annual cost per patient increased from approximately 13,300 CZK to 17,000 CZK, which officials attribute to more expensive treatment options and the overall health status of patients.
Entities
Czech Diabetes Society · Czechia · Health Insurance Fund of the Ministry of the Interior · Ladislav Hadravský · Martin Prázný